Carbapenem-resistant Enterobacterales in solid organ transplant recipients
- PMID: 39522694
- PMCID: PMC11997972
- DOI: 10.1016/j.ajt.2024.10.020
Carbapenem-resistant Enterobacterales in solid organ transplant recipients
Abstract
Carbapenem-resistant Enterobacterales (CRE) are an important threat to the health of solid organ transplant recipients (SOTr); data comparing outcomes of SOTr with CRE to non-SOTr with CRE are lacking. A matched cohort study was performed within 2 prospective, multicenter, cohort studies (Consortium on Resistance Against Carbapenems in Klebsiella and other Enterobacterales and Consortium on Resistance Against Carbapenems in Klebsiella and other Enterobacterales 2). The epidemiology, desirability of outcome rankings outcomes, and mortality of SOTr and non-SOTr hospitalized in the United States (December 2011-August 2017) with clinical isolates with Centers for Disease Control and Prevention-defined CRE were compared. In total, 121 SOTr and 242 matched non-SOTr were included. Fifty-one percent of isolates met infection criteria. SOTr were younger (P < .001), less acutely ill (P = .029), less often had a malignancy history (P = .006), and more often were admitted from home (P < .001) than non-SOTr. SOTr had more favorable adjusted desirability of outcome rankings outcomes; a randomly selected SOTr had a 58% (95% confidence interval, 53%-64%) probability of a better outcome as compared to a randomly selected non-SOTr. All-cause 30-day mortality was 14% (17/121) in SOTr vs 25% (60/242) in non-SOTr, P = .018. After stabilized inverse probability weighted adjustment, SOTr had a 7% lower 30-day mortality risk than non-SOTr (95% confidence interval, -15% to 1%). SOTr with CRE do not have worse outcomes than matched patients without transplant history.
Keywords: carbapenem-resistant Enterobacterales; epidemiology; mortality; solid organ transplantation.
Copyright © 2024 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors of this manuscript have conflicts of interest to disclose as described by American Journal of Transplantation. All authors report funding support from the ARLG of the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID; UM1AI104681) during the conduct of this study. W. Dai, E. Cober, L. Komarow, L. Chen, C. Hill, M. Grant, and G. Patel have nothing to declare other than the ARLG grant paid to their institution. A.E. Boutzoukas reports NIH grants and contracts paid to her institution, research support from the Thrasher Research Foundation, and support from the Biogen Foundation. L.M. Abbo reports honorarium for ontinuing medical education (CM lectures from Pfizer Latin America and Merck Sharp & Dohme Latin America related to the study; and in the last 3 years consulting honorarium from bioMéreiux, Shionogi, Ferring pharmaceuticals, Pfizer, La Joya, Abbvie Therapeutics; and speaker honorarium for CME lectures from Medscape and Clinical Care options. M.J. Satlin reports grants/contracts to his institution from Merck, Selux Diagnostics, SNIPRBiome, and bioMéreiux; consulting fees paid directly to him from Shionogi; and compensation for participation on a data and safety monitoring board from AbbVie paid directly to him. B.C. Fries reports support from the USVeterans Affairs Merit Review Award 5I01 BX003741 and the National Institute for Allergy Infectious Diseases R01AI181830; is an attending at the US Department of Veterans Affairs, Northport Veterans Affairs (VA) Medical Center, Northport, NY; contents of this review do not represent the views of the VA or the United States Government. T.P. McCarty reports a research contract paid to his institution from T2Biosystems. C.A. Arias reports the following grants and contracts paid to his institution NIH/NIAID 1 P01 AI152999, NIH/NIAID R01 AI148342, NIH/NIAID R01 AI134637, NIH/NIAID T32 AI141349, NIH/NIAID K24 AI121296, NIH/NIAID U19 AI144297, and NIH/NIAID R01 AI150685; payments to him for UpToDate royalties; reimbursement of meeting attendance and speaking from Infectious Diseases Society of America, American Society for Microbiology, Society of Hospital Epidemiology of America, European Society for Clinical Microbiology and Infectious Diseases, Mérieux Foundation, Sociedad Argentina de Infectologia, Sociedad Chilena de Infectologia, Sociedad Colombiana de Infectologia, Panamerican Society for Infectious Diseases, and Brazilian Society for Infectious Diseases; reviewer participation as part of the NIH grant Review Study Sections; travel expenses from the Infectious Disease Society of America Board of Directors; and for Editor in Chief for Antimicrobial Agents and Chemotherapy; nonpaid participation includes World Health Organization Antibacterial Pipeline Advisory Group, and participation on the Infectious Disease Society of America Board of Directors. R.A. Bonomo reports grants and contracts, paid to his institution, by VenatoRx and Merck; payments made to him by Pfizer to moderate meeting sessions; a provisional patent with Case Western Reserve University on the development of boronic acid transition state inhibitors for beta-lactamases; served on a data and safety monitoring board as a logistics associate for Division of Microbiology and Infectious Diseases-Clinical Research Operations and Management Support, Safety Oversight Committee Support; and Technical Resources International, Inc. D. van Duin reports grants and contracts from the NIH, Merck, and Shinogi, paid to his institution, outside of the published work; consultancy for Actavis, Tetraphase, Sanofi-Pasteur, MedImmune, Astellas, Merck, Allergan, T2Biosystems, Roche, Achaogen, Neumedicine, Shionogi, Pfizer, Entasis, Qpex, Wellspring, Karius, and Utility, paid directly to him; honoraria from Pfizer; and an editor’s stipend from the British Society for Antimicrobial Chemotherapy.
Figures

References
-
- Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: US Department of Health and Human Services.
-
- Perez-Nadales E, Fernandez-Ruiz M, Gutierrez-Gutierrez B, et al. Extended-spectrum beta-lactamase-producing and carbapenem-resistant Enterobacterales bloodstream infection after solid organ transplantation: recent trends in epidemiology and therapeutic approaches. Transpl Infect Dis. Jun 12 2022;doi:10.1111/tid.13881 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous